{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:01:51Z","timestamp":1762506111010},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/spc.0b013e328356da87","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:23:54Z","timestamp":1371158634000},"page":"299-303","source":"Crossref","is-referenced-by-count":5,"title":["Preventing bone complications in prostate cancer"],"prefix":"10.1097","volume":"6","author":[{"given":"Mohamed","family":"Bishr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20211004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010.","volume":"60","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-2-20211004","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer.","volume":"294","author":"Sharifi","year":"2005","journal-title":"J Am Med Assoc"},{"key":"R3-2-20211004","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1200\/JCO.2007.11.1559","article-title":"Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.","volume":"25","author":"Antonarakis","year":"2007","journal-title":"J Clin Oncol"},{"key":"R5-2-20211004","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"key":"R7-2-20211004","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates.","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"R9-2-20211004","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound.","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"R10-2-20211004","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5489\/cuaj.811","article-title":"Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.","volume":"4","author":"Egerdie","year":"2010","journal-title":"CUAJ"},{"key":"R11-2-20211004","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R12-2-20211004","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R13-2-20211004","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"R15-2-20211004","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation.","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"R16-2-20211004","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer.","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"R17-2-20211004","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"R18-2-20211004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"R19-2-20211004","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","article-title":"The relationship between daily calcium intake and bone mineral density in men with prostate cancer.","volume":"99","author":"Planas","year":"2007","journal-title":"BJU Int"},{"key":"R20-2-20211004","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R21-2-20211004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"key":"R22-2-20211004","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-2-20211004","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.","volume":"179","author":"Smith","year":"2008","journal-title":"J Urol"},{"key":"R24-2-20211004","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","article-title":"Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201209000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T06:38:49Z","timestamp":1633502329000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201209000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e328356da87","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}